Dasatinib-induced hypoglycemia in a patient with acute lymphoblastic leukemia

被引：5

作者：

Lundholm, Michelle D. ^{[1
]}

Charnogursky, Gerald A. ^{[2
]}

机构：

[1] Loyola Univ Med Ctr, Dept Internal Med, 2160 S First Ave, Maywood, IL 60153 USA

[2] Loyola Univ Hlth Care Syst, Dept Med, Div Endocrinol, Maywood, IL USA

来源：

CLINICAL CASE REPORTS | 2020年 / 8卷 / 07期

关键词：

acute lymphoblastic leukemia; adverse effect; diabetes; hypoglycemia; tyrosine kinase inhibitor; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; IMATINIB MESYLATE; GLUCOSE;

D O I：

10.1002/ccr3.2901

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tyrosine kinase inhibitors can cause significant hypoglycemia in patients with diabetes on other antihyperglycemic medications. These patients should be monitored, and their medications adjusted accordingly.

引用

页码：1238 / 1240

页数：3

共 50 条

[41] Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
Inoue, Hiroyasu
Taji, Hirofumi
Yamada, Kentaro
Iriyama, Chisako
Saito, Touko
Kato, Harumi
Yanada, Masamitsu
Yamamoto, Kazuhito
Matsukawa, Noriyuki
[J]. INTERNAL MEDICINE, 2020, 59 (19) : 2419 - 2421
[42] Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib
Sekimizu, Masahiro
Yamashita, Yuka
Ueki, Hideaki
Akita, Nobuhiro
Hattori, Hiroyoshi
Maeda, Naoko
Horibe, Keizo
[J]. LEUKEMIA & LYMPHOMA, 2014, 55 (07) : 1652 - 1653
[43] Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion
Anna Czyz
Krzysztof Lewandowski
Renata Kroll
Mieczysław Komarnicki
[J]. Medical Oncology, 2010, 27 : 1123 - 1126
[44] Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion
Czyz, Anna
Lewandowski, Krzysztof
Kroll, Renata
Komarnicki, Mieczyslaw
[J]. MEDICAL ONCOLOGY, 2010, 27 (04) : 1123 - 1126
[45] Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes
Xue, Tao
Luo, Peihua
Zhu, Hong
Zhao, Yuqin
Wu, Honghai
Gai, Renhua
Wu, Youping
Yang, Bo
Yang, Xiaochun
He, Qiaojun
[J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2012, 261 (03) : 280 - 291
[46] Dasatinib-induced follicular lymphoid hyperplasia, an entity to know
Phelippeau, Mona
Lefebvre, Christine
Jacob, Marie-Christine
Syrykh, Charlotte
Ghelfi, Julien
Carras, Sylvain
Laurent, Camille
Molina, Lysiane
Valmary-Degano, Severine
[J]. ANNALES DE PATHOLOGIE, 2023, 43 (01) : 45 - 51
[47] Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?
Goldblatt, Mark
Huggins, J. Terrill
Doelken, Peter
Gurung, Puncho
Sahn, Steven A.
[J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 338 (05) : 414 - 417
[48] Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
Nagata, Yasunobu
Ohashi, Kazuteru
Fukuda, Shiomi
Kamata, Noriko
Akiyama, Hideki
Sakamaki, Hisashi
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (05) : 799 - 807
[49] Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
Brattas, Marte Karen
Reikvam, Hakon
Tvedt, Tor Henrik Anderson
Bruserud, Oystein
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (05) : 411 - 420
[50] The Hidden Variable: A Case of Dasatinib-Induced Respiratory Failure
Drekolias, Dimitrios
Gadela, Naga Vaishnavi
Syeda, Asma
Jacob, Jason
[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)

← 1 2 3 4 5 →